MarketCap
Facebook
X
Telegram
Harrow Health EBITDA | HROW
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Harrow Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.8 M | 10.1 M | 1.49 M | 3.17 M | 3.19 M | 3.49 M | 1.9 M | -3.37 M | -10.4 M | -14.2 M | -14.2 M | -10.1 M | -7.68 M | -4.18 M | -939 K | -2.5 M | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.8 M | -14.2 M | -772 K |
Quarterly EBITDA Harrow Health
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17 M | -5.48 M | -17 M | 19.9 M | 19 M | 15.6 M | -7.01 M | 17 M | 3.93 M | 4.08 M | -4.37 M | -2.43 M | 4.33 M | 5.2 M | 3.42 M | -1.4 M | 304 K | 2.09 M | 2.5 M | -1.72 M | -3.67 M | 4.21 M | 2.96 M | 2.67 M | 1.64 M | -3.17 M | -583 K | 960 K | -4.35 M | -704 K | -494 K | -2.1 M | -593 K | -567 K | -1.72 M | -2.06 M | -2.68 M | -2.92 M | -4.14 M | -3.42 M | -4.53 M | -3.92 M | -3.66 M | -4.6 M | -3.44 M | -3.39 M | -3.04 M | -2.73 M | -2.45 M | -2.59 M | -2.33 M | -1.89 M | -2.09 M | -2.23 M | -1.47 M | - | -1.25 M | -1.12 M | -352 K | - | -66.5 K | -146 K | -414 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19.9 M | -17 M | 108 K |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Drug manufacturers industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
TherapeuticsMD
TXMD
|
-4.01 M | $ 1.74 | 2.96 % | $ 20.1 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M | USA |
 |
Assertio Holdings
ASRT
|
8.47 M | - | - | $ 150 M | USA |
 |
Jupiter Wellness
JUPW
|
654 K | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-100 M | - | - | $ 193 M |  Canada |
 |
ProPhase Labs
PRPH
|
-13.2 M | - | - | $ 5.07 M | USA |
 |
Zomedica Corp.
ZOM
|
-82.3 M | - | -0.21 % | $ 98 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-39.7 M | - | - | $ 2.06 B |  France |
 |
Pacira BioSciences
PCRX
|
110 M | $ 36.48 | 0.04 % | $ 1.63 B | USA |
 |
Perrigo Company plc
PRGO
|
-785 M | $ 16.83 | -0.71 % | $ 2.33 B | USA |
 |
Evoke Pharma
EVOK
|
-5.2 M | - | - | $ 36.6 M | USA |
 |
Solid Biosciences
SLDB
|
-178 M | $ 7.19 | 2.35 % | $ 629 M | USA |
 |
Sundial Growers
SNDL
|
-6.35 M | $ 1.4 | -0.36 % | $ 361 M | Canada |
 |
Tilray
TLRY
|
-63 M | $ 2.66 | -6.84 % | $ 297 M | Canada |
 |
Aerie Pharmaceuticals
AERI
|
-40 M | - | - | $ 754 M | USA |
 |
Veru
VERU
|
-24.6 M | $ 2.12 | -3.2 % | $ 31.1 M | USA |
 |
Viatris
VTRS
|
135 M | $ 20.86 | 1.81 % | $ 23.9 B | USA |
 |
Alimera Sciences
ALIM
|
6.82 M | - | - | $ 142 M | USA |
 |
cbdMD
YCBD
|
-1.8 M | $ 0.39 | 1.86 % | $ 1.57 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-23.6 M | - | 0.86 % | $ 117 M | USA |
 |
China Pharma Holdings
CPHI
|
-1.74 M | $ 0.55 | -2.64 % | $ 2.36 M |  China |
 |
Lannett Company
LCI
|
-142 M | - | 1.15 % | $ 7.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
PetIQ
PETQ
|
81.6 M | - | 1.64 % | $ 400 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
DURECT Corporation
DRRX
|
-18.8 M | - | - | $ 50.1 M | USA |
 |
Athenex
ATNX
|
-65.5 M | - | -23.39 % | $ 1.76 M | USA |
 |
PLx Pharma
PLXP
|
-40.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Catalent
CTLT
|
-260 M | - | - | $ 11.5 B | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
OptiNose
OPTN
|
-16 M | - | - | $ 1.08 B | USA |
 |
Radius Health
RDUS
|
-53.2 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
4.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Canopy Growth Corporation
CGC
|
-143 M | $ 0.59 | -5.37 % | $ 176 M | Canada |
 |
Aurora Cannabis
ACB
|
4.95 M | $ 5.11 | -1.07 % | $ 280 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
2.77 M | $ 5.39 | 0.37 % | $ 80.1 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 4.24 | 2.42 % | $ 167 M | USA |
 |
Emergent BioSolutions
EBS
|
196 M | $ 6.04 | -0.98 % | $ 323 M | USA |
 |
Cronos Group
CRON
|
-3.16 M | $ 3.43 | -3.25 % | $ 1.32 B | Canada |
 |
Evolus
EOLS
|
-25.2 M | $ 6.81 | -2.51 % | $ 439 M | USA |
 |
Organogenesis Holdings
ORGO
|
60 M | $ 0.96 | 5.83 % | $ 122 M | USA |
 |
Bausch Health Companies
BHC
|
3.02 B | $ 8.33 | -0.83 % | $ 3.09 B | Canada |
 |
OrganiGram Holdings
OGI
|
-35.7 M | $ 0.85 | -2.69 % | $ 81 M | Canada |
 |
Rockwell Medical
RMTI
|
-2.5 M | $ 7.35 | -2.26 % | $ 264 M | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 3.54 | 1.14 % | $ 177 M | USA |
 |
HEXO Corp.
HEXO
|
-1.07 B | - | 2.45 % | $ 38.1 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-373 M | - | -0.1 % | $ 2.03 B |  Schweden |